Podocalyxin-like protein 1 functions as an immunomodulatory molecule in breast cancer cells.

[1]  A. Diez-Juan,et al.  Podocalyxin‐like protein 1 is a relevant marker for human c‐kitpos cardiac stem cells , 2016, Journal of tissue engineering and regenerative medicine.

[2]  Cathrine A. Miner,et al.  Acquisition of Activation Receptor Ligand by Trogocytosis Renders NK Cells Hyporesponsive , 2015, The Journal of Immunology.

[3]  S. Holland,et al.  Intact IL-12 signaling is necessary for the generation of human natural killer cells with enhanced effector function after restimulation. , 2014, The Journal of allergy and clinical immunology.

[4]  John Yu,et al.  Podocalyxin-like 1 promotes invadopodia formation and metastasis through activation of Rac1/Cdc42/cortactin signaling in breast cancer cells. , 2014, Carcinogenesis.

[5]  Han‐Chung Wu,et al.  Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma. , 2014, International journal of oncology.

[6]  G. Adema,et al.  Sialic acids sweeten a tumor's life. , 2014, Cancer research.

[7]  M. Moser,et al.  Regulation of Immune Reactivity by Intercellular Transfer , 2014, Front. Immunol..

[8]  Xinguo Jiang,et al.  The immune system and inflammation in breast cancer , 2014, Molecular and Cellular Endocrinology.

[9]  J. Rautela,et al.  The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. , 2013, Cancer research.

[10]  M. Uhlén,et al.  Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer , 2013, British Journal of Cancer.

[11]  M. Cheng,et al.  NK cell-based immunotherapy for malignant diseases , 2013, Cellular and Molecular Immunology.

[12]  B. Fingleton,et al.  Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. , 2012, Cancer research.

[13]  J. Sparano,et al.  T cell coinhibition and immunotherapy in human breast cancer. , 2012, Discovery medicine.

[14]  Michael Loran Dustin,et al.  Signaling at neuro/immune synapses. , 2012, The Journal of clinical investigation.

[15]  M. Köbel,et al.  The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma , 2012, Clinical & Experimental Metastasis.

[16]  H. Putter,et al.  NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study , 2012, BMC Cancer.

[17]  F. Bertucci,et al.  Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. , 2011, Cancer research.

[18]  F. Bertucci,et al.  Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. , 2011, The Journal of clinical investigation.

[19]  K. Jirström,et al.  Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer , 2011, British Journal of Cancer.

[20]  J. Wilkins,et al.  Requirement of Podocalyxin in TGF-Beta Induced Epithelial Mesenchymal Transition , 2011, PloS one.

[21]  H. Putter,et al.  HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients , 2010, The Journal of Immunology.

[22]  E. Soriano,et al.  Podocalyxin Is a Novel Polysialylated Neural Adhesion Protein with Multiple Roles in Neural Development and Synapse Formation , 2010, PloS one.

[23]  C. Shun,et al.  Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. , 2010, The American journal of pathology.

[24]  Kai Yu,et al.  Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice , 2010, Breast Cancer Research and Treatment.

[25]  C. Rancourt,et al.  MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells , 2010, Molecular Cancer.

[26]  J. Nielsen,et al.  The role of podocalyxin in health and disease. , 2009, Journal of the American Society of Nephrology : JASN.

[27]  M. Barcellos-Hoff,et al.  Transforming growth factor-β in breast cancer: too much, too late , 2009, Breast Cancer Research.

[28]  J. Orange.  Formation and function of the lytic NK-cell immunological synapse , 2008, Nature Reviews Immunology.

[29]  G. Casey,et al.  Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. , 2007, Cancer research.

[30]  P. Moreau,et al.  Trogocytosis‐based generation of suppressive NK cells , 2007, The EMBO journal.

[31]  E. Carosella,et al.  Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. , 2006, Blood.

[32]  J. Witte,et al.  Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. , 2006, Human molecular genetics.

[33]  R. Wolfram,et al.  Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer. , 2006, European journal of medical research.

[34]  J. Dausset,et al.  Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Dering,et al.  HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells , 2005, Breast Cancer Research.

[36]  I. Ellis,et al.  Total loss of MHC class I is an independent indicator of good prognosis in breast cancer , 2005, International journal of cancer.

[37]  J. A. Lopez,et al.  Dendritic cell dysfunction in cancer: A mechanism for immunosuppression , 2005, Immunology and cell biology.

[38]  Lewis L Lanier,et al.  NK cell recognition. , 2005, Annual review of immunology.

[39]  D. Huntsman,et al.  Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression , 2004, Cancer Research.

[40]  J. Schatzle,et al.  Stepwise cytoskeletal polarization as a series of checkpoints in innate but not adaptive cytolytic killing , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Sarker,et al.  Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells , 2002, Oncogene.

[42]  M. Ross,et al.  Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. , 1998, Journal of immunology.

[43]  C. Sassetti,et al.  Identification of Podocalyxin-like Protein as a High Endothelial Venule Ligand for L-selectin: Parallels to CD34 , 1998, The Journal of experimental medicine.

[44]  D. Kerjaschki,et al.  Identification and characterization of podocalyxin--the major sialoprotein of the renal glomerular epithelial cell , 1984, The Journal of cell biology.